Helicore Biopharma Launches with $65M to Target GIP for Improved Weight Loss
• Helicore Biopharma, backed by Versant Ventures and OrbiMed, launches with $65 million in Series A funding to develop GIP-targeting therapies for obesity.
• The lead asset, HCR-188, a monoclonal antibody against GIP, is expected to enter clinical trials this year, with topline data anticipated in late 2025.
• Helicore aims to differentiate itself through GIP antibody conjugates, potentially combined with GLP-1 therapies, to target specific obesity subpopulations.
• Preclinical data suggest HCR-188, especially with GLP-1 therapies, may induce preferential fat loss over lean mass, addressing a key challenge in obesity treatment.
© Copyright 2025. All Rights Reserved by MedPath